Mode
Text Size
Log in / Sign up
Phase 3 Completed N=924 Randomized Quadruple-blind Treatment

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

Source: ClinicalTrials.gov NCT03287791 ↗
Enrolled (actual)
924
Serious AEs
0.3%
Results posted
Jul 2019
Primary outcomePrimary: Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12 — -64.28; -65.15; -57.84 percent change — p=<.0001

Summary

The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of the two active foams in the treatment of moderate facial rosacea, and to demonstrate superiority of the Reference and Test products over the Vehicle.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12
-64.28; -65.15; -57.84 <.0001 sig
SECONDARY
Percentage of Participants With Treatment Success Based on IGE Score
39.7; 48.3; 33.5

Eligibility Criteria

Inclusion Criteria

  • Participants had to be willing and able to provide written informed consent for the study
  • Healthy males or non-pregnant females ≥18 years-of-age with a clinical diagnosis of moderate facial rosacea
  • Participants had to have at least 8 and not more than 50 inflammatory facial lesions (that is, papules/pustules) and ≤2 nodules on the face. For the purposes of study treatment and evaluation, these lesions were limited to the facial treatment area including those present on the nose. Lesions involving the eyes and scalp were excluded from the count.
  • Participants had to have persistent erythema on the face with moderate (3) score
  • Participants had to have a mild (1) to moderate (2) score for telangiectasia on the face
  • Participants had to have a definite clinical diagnosis of moderate facial rosacea (severity score 3)
  • Participants had to be willing to minimize external factors that might trigger rosacea flare-ups (for example, spicy foods, thermally hot foods and drinks, hot environments, prolonged sun exposure, strong winds, and alcoholic beverages) during the course of the study
  • Participants had to be in general good health and free from any clinically significant disease other than rosacea on the face, that could have interfered with the study evaluations
  • Participants had to be willing and able to understand and comply with the requirements of the study, apply the medication as instructed, return for the required treatment period visits, comply with therapy prohibitions, and able to complete the study
  • Male participants and female participants of childbearing potential had to use accepted methods of birth control or had to agree to practice abstinence, from study start to 30 days after the last administration of study drug. All female participants were considered to be of childbearing potential unless they had been surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or had been postmenopausal for at least a year. Any of the following methods of birth control were acceptable: oral contraceptives, contraceptive patches/implants (for example, Norplant®), vaginal ring (NuvaRing®), Depo-Provera® (Medroxy progesterone acetate), double barrier methods (for example, condom and spermicide), or intrauterine device
  • Female participants of child bearing potential had to have a negative urine pregnancy test at baseline
  • Participants who used make-up had to have used the same brands/types of make-up for a minimum period of 14 days prior to study entry and had to agree to use the same make-up, brand/type, or frequency of use, throughout the study

Exclusion Criteria

  • Pregnant or lactating or planning to become pregnant during the study period
  • Presence of any skin condition on the face that could have interfered with the diagnosis or assessment of rosacea
  • Excessive facial hair (for example, beards, sideburns, moustaches) that would interfere could have interfered with diagnosis or assessment of rosacea
  • History of hypersensitivity or allergy to azelaic acid, propylene glycol, or any other component of the formulation
  • The use within 6 months prior to baseline of oral retinoids (for example, Accutane®) or therapeutic Vitamin A supplements of greater than 10,000 units/day (multivitamins were allowed)
  • The use of estrogens or oral contraceptives for less than 3 months prior to baseline
  • The use within 1 month prior to baseline of the following:
  • topical retinoids to the face
  • systemic antibiotics known to have an impact on the severity of facial rosacea (for example, containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim)
  • systemic corticosteroids
  • Use within two weeks prior to baseline of the following:
  • topical corticosteroids
  • topical antibiotics
  • topical medications for rosacea (for example, metronidazole, azelaic acid)
  • Antipruritics, including antihistamines, within 24 hours of any study visit
  • Pa
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03287791). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search